Clinical Development of Darolutamide: A Novel Androgen Receptor Antagonist for the Treatment of Prostate Cancer

Clinical Genitourinary Cancer - United States
doi 10.1016/j.clgc.2018.07.017
Full Text
Abstract

Available in full text

Categories
OncologyUrology
Date
Authors
Publisher

Elsevier BV

Related search

An Androgen Receptor N-Terminal Domain Antagonist for Treating Prostate Cancer

Journal of Clinical Investigation
Medicine
2013English

Discovery and Mechanistic Characterization of a Novel Selective Nuclear Androgen Receptor Exporter for the Treatment of Prostate Cancer

Cancer Research
Cancer ResearchOncology
2010English

Lupeol, a Novel Androgen Receptor Inhibitor: Implications in Prostate Cancer Therapy

Clinical Cancer Research
Cancer ResearchOncology
2011English

The Liver X Receptor Agonist T0901317 Acts as Androgen Receptor Antagonist in Human Prostate Cancer Cells

Biochemical and Biophysical Research Communications
BiochemistryCell BiologyMolecular BiologyBiophysics
2007English

Looking Beyond Androgen Receptor Signaling in the Treatment of Advanced Prostate Cancer

Advances in Andrology
2014English

A Novel Nonsense Mutation in Androgen Receptor Confers Resistance to CYP17 Inhibitor Treatment in Prostate Cancer

Oncotarget
Oncology
2016English

Treatment of Androgen‐Independent Prostate Cancer

Oncologist
Cancer ResearchMedicineOncology
1996English

The Androgen Receptor and Prostate Cancer Invasion

Molecular and Cellular Endocrinology
BiochemistryEndocrinologyMolecular Biology
2006English

Androgen Receptor Corepressors and Prostate Cancer

Endocrine-Related Cancer
Cancer ResearchEndocrinologyOncologyMetabolismDiabetes
2006English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy